You are here

Article Text

Article menu
Download PDFPDF
Editorial commentary
What should we do about vaccination of patients on anti-CD20 antibody therapy?
  1. Takayoshi Shimohata
  1. Department of Neurology, Gifu University Graduate School of Medicine, Gifu, Japan
  1. Correspondence to Professor Takayoshi Shimohata, Neurology, Gifu University, Gifu 501-1194, Japan; shimohata{at}gmail.com

https://doi.org/10.1136/jnnp-2021-327371

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The SARS-CoV-2 antibody response was decreased in patients with multiple sclerosis (MS) who were infected with COVID-19 and received anti-CD20 therapy

    Vaccination efforts for COVID-19 are currently underway worldwide. At present, there is insufficient evidence of the vaccine’s efficacy and safety in patients with neurological diseases, such as stroke, dementia and intractable neurological diseases. Despite the fact that many patients with neurological diseases are elderly and often have systemic complications, I believe that neurologists should nonetheless actively recommend vaccination to their patients. However, there are at least three problems that I encounter in my daily clinical practice when I vaccinate patients with neurological diseases.

    The first problem is that many patients with dementia have no family members or other relatives, and self-determination for vaccination is difficult. The second problem is …

    View Full Text

    Footnotes

    • Contributors I am a reviewer of the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles

    • Multiple sclerosis
      Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders
      Céline Louapre Michella Ibrahim Elisabeth Maillart Basma Abdi Caroline Papeix Bruno Stankoff Anne-Laure Dubessy Caroline Bensa-Koscher Alain Créange Zina Chamekh Catherine Lubetzki Anne-Geneviève Marcelin Jean-Christophe Corvol Valérie Pourcher COVISEP and Bio-coco-neuroscience study group Salimata Gassama Sara Sambin Cécile Delorme Edouard Januel Thomas Roux Raphael De Paz Ysoline Beigneux Vito Ricigliano Rabab Debs Abir Wahab Jennifer Aboab Maya Tchikviladze Yanica Mathieu Amandine Bordet Amandine Hippolyte Aurélie Fekete Sandrine Sagnes Sylvie Forlani
      Journal of Neurology, Neurosurgery & Psychiatry 2021; 93 24-31 Published Online First: 02 Aug 2021. doi: 10.1136/jnnp-2021-326904